Sprouty proteins function as negative regulators of the receptor tyrosine kinase (RTK)-mediated Ras/Raf/ MAPK pathway in many varied physiological and developmental processes, inhibiting growth factorinduced cellular proliferation, migration and differentiation. Like other negative regulators, Sprouty proteins are expressed in various organs during development, including the eye; ubiquitously expressed in the optic vesicle, lens pit, optic cup and lens vesicle. Given the synexpression of different antagonists (e.g, Sprouty, Sef, Spred) in the developing lens, to gain a better understanding of their specific role, in particular, their ability to regulate ocular growth factor signaling in lens cells, we characterized transgenic mice overexpressing Sprouty1 or Sprouty2 in the eye. Overexpression of Sprouty in the lens resulted in reduced lens and eye size during ocular morphogenesis, influenced by changes to the lens epithelium, aberrant fiber cell differentiation and compromised de novo maintenance of the lens capsule.
Sprouty (Spry) proteins function as key regulators of various physiological and developmental processes, including angiogenesis, lung morphogenesis, limb formation, and bone, kidney, eye and wing development (Chi et al., 2004; Impagnatiello et al., 2001; Lee et al., 2001; Mailleux et al., 2001; Minowada et al., 1999; Tefft et al., 1999; Yigzaw et al., 2001) . In common with other negative regulators, including Sef and Spreds (Sprouty-related proteins), members of the Spry protein family repress the receptor tyrosine kinase (RTK)-mediated Ras/Raf/MAPK pathway (Bundschu et al., 2007; Cabrita and Christofori, 2008; Mason et al., 2006; Ron et al., 2008) , and are reported to inhibit growth factor-induced cellular proliferation, migration and differentiation (Gross et al., 2001; Lee et al., 2004; Yigzaw et al., 2001) . In mammals, Spry proteins negatively regulate high affinity RTK-signaling, such as FGF receptor- (Gross et al., 2001; Hanafusa et al., 2002) and PDGF-receptor signaling (Gross et al., 2001; Yigzaw et al., 2001) . This inhibitory function of Spry is directed at numerous levels of the Ras/ ERK pathway, such as Grb2, FRS2, C-Raf and Shp2 (Kim and Bar-Sagi, 2004; Mason et al., 2006) . In some cellular contexts; however, different Spry isoforms (e.g. Spry2) are reported to enhance EGF-mediated signaling (Egan et al., 2002; Wong et al., 2002) , by interfering with the c-Cbl-mediated ubiquitylation and degradation of the EGF receptor (Levkowitz et al., 1998; Rubin et al., 2003; Soubeyran et al., 2002; Wong et al., 2001) .
Similar to Sef and Spred, Spry proteins are expressed in various organs, including the eye (Boros et al., 2006; Zhao et al., 2015) . In rodents, Spry1 and Spry2 transcripts are expressed ubiquitously in the optic vesicle at embryonic day 9.5 (E9.5); the lens pit and optic cup at E10.5; and the lens epithelium and primary lens fibers at E12.5 (Boros et al., 2006) . By E15.5, Spry1 mRNA expression is mainly restricted to the lens epithelium and the early secondary lens fibers, and persists throughout fetal and postnatal lens growth. The expression pattern of Spry2 transcripts is similar to that of Spry1 during early ocular morphogenesis, ubiquitously Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/developmentalbiology expressed in the optic vesicle, lens pit, optic cup and lens vesicle from E9.5 to E12.5 (Boros et al., 2006) . In contrast to Spry1, from E13.5 until early postnatal age P3, Spry2 transcripts are detected both in the lens epithelium and the entire fiber cell mass. With further postnatal growth, Spry2 mRNA expression in the primary fibers progressively disappears, with expression limited to the lens epithelium and early secondary fibers, decreasing with age (Boros et al., 2006) .
Of the many growth factors present in the ocular environment, FGF is one of the key molecules to induce both lens epithelial cell proliferation and fiber differentiation (see Lovicu and McAvoy, 2005) . Our earlier studies reported that overexpression of Sef in lens of mice could block fiber cell elongation associated with its differentiation, repressing lens and eye growth (Newitt et al., 2010) . These findings were reminiscent of lenses deficient for FGFR1-3 (Zhao et al., 2008) , both displaying a similar phenotype. Given the overlapping patterns of expression of Sef with Spry in the developing lens, to gain a better understanding of the role of these different antagonists in lens development, in particular, their ability to regulate ocular growth factor signaling in lens cells, we generated transgenic mice overexpressing Spry1 or Spry2 in the eye. Whilst our earlier studies reported little response in lens of transgenic mice hemizygous for the Spry1 transgene (Shin et al., 2012) ; here we demonstrate that higher levels of Spry1 expression in the lens (in transgenic mice homozygous for the Spry1 transgene), influences lens cellular processes and subsequent lens and eye growth, similar to overexpression of Spry2, but different to that previously reported for Sef (Newitt et al., 2010) . Whilst growth factor regulation of lens cell proliferation and fiber differentiation are required for orchestrating lens morphogenesis and growth, in turn antagonists such as Spry and Sef are just as important for regulating the intracellular signaling pathways driving lens cellular processes.
Materials and methods
All animal procedures were carried out in accordance with the National Health Medical Research Council (Australia) guidelines and the Association for Research in Vision and Ophthalmology Handbook for the Use of Animals in Biomedical Research (USA). All protocols were approved by the Animal Ethics Review Committee of the University of Sydney, Australia.
Animals
The different Cre-expressing lines of mice (Le-Cre and MLR10-Cre) were provided by Dr. Michael Robinson. For the Le-Cre line, Cre-recombinase is expressed in the developing lens, cornea, conjunctiva and skin of the eyelids from E9 (Ashery-Padan et al., 2000) , while Cre-expression in the MLR10-Cre line is restricted to the lens epithelial and fiber cells (Zhao et al., 2004) . To overexpress Spry2 in the eye, these Cre-lines were crossed to MS2GOF (inducible Spry 2 gain of function) transgenic mice, provided by Dr. Gail Martin (Basson et al., 2008) . For simplicity, the resultant mice from these crosses will be referred to as Spry2 GOF . Only transgenic mice heterozygous for both the MS2GOF and Le-Cre transgene were characterised here, given those crossed to MLR10-Cre demonstrated a similar lens phenotype. The Spry1 overexpressing transgenic lines (LOV28-LOV31) were generated on a FVB/N background as previously described using a modified αA-crystallin promoter, fused to a chick δ1-crystallin enhancer element (Shin et al., 2012) . For consistency, we will refer to these as Spry1 GOF . Genotypes were determined by PCR assays using tail DNA as a template, as previously described (Ashery-Padan et al., 2000; Zhao et al., 2004; Basson et al., 2008; Shin et al., 2012) . For lens explant studies, the ocular tissues were obtained from either the different lines of transgenic mice or postnatal albino Wistar rats.
Histological processing
Whole eyes of postnatal animals ranging in age from postnatal day 0 (P0) to P21 were fixed in 10% (v/v) neutral-buffered formalin (NBF, Fronine Laboratory Supplies, Australia), and processed for paraffin embedding (Excelsior ES tissue processor, Thermo Scientific, MA, USA). Tissue sections were mid-sagittally cut at 6 μm, and routinely stained with either Haematoxylin and Eosin (H&E) or Periodic-Acid Schiff (PAS). Tissues were visualized with bright field microscopy (Leica DMLB; Germany) and digitally photographed (QCapture, QImaging; BC, Canada). As required, images taken from up to five mid-sagittal sections of lenses from four different eyes for each of the different lines of mice, were used to calculate the average number of lens epithelial cells, and Student's t-test was performed for statistical evaluation.
Preparation of lens epithelial explants
All tissue culture was performed in Medium 199 with Earle's salts (M199; Invitrogen, CA, USA). M199 was supplemented with 0.1 mg/ml L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 2.5 mg/ml amphostat B (Thermo Electron, MA, USA) and 0.1% tissue culture grade BSA (Sigma-Aldrich, Australia). Eyes from either P7 WT, Spry1 GOF , Spry2 GOF or postnatal day 10 (P10) wistar rats were used to obtain lenses, that were subsequently dissected to isolate the lens epithelium as previously described (Lovicu and McAvoy, 2008) . All growth factors applied to lens explants were prepared as per manufacturer's instructions. Human recombinant FGF2 (R&D Systems; MN, USA) was used at concentrations of 5 ng/ml, 50 ng/ml, or 100 ng/ml. EGF (R&D Systems) was used at a concentration of 50 ng/ml or 100 ng/ml. Explants were cultured in the presence of growth factors from 20 min to up to 10 days. Some explants were treated with selective inhibitors for PI3-K signaling (25 mM LY294002; Calbiochem, CA, USA), or dimethyl sulfoxide (DMSO, control dishes), as previously described (Iyengar et al., 2006) . Cultured explants were either collected fresh for protein extraction for western blot analysis, or fixed in 10% NBF, pre-embedded in 3% agar in PBS before paraffin embedding, sectioning and staining, as described earlier for histological processing.
DNA transfection of lens epithelial explants
Rat lens epithelial explants were transfected with DNA plasmids of interest (pLXSG, pLXSG-Sprouty1, pLXSG-Sprouty2, pLXSG-ΔSprouty2 and pLXSG-dnFGFR) using Lipofectamine 2000 (Invitrogen, USA) as previously described (Zhao et al., 2015) . Transfected cells in explants expressed the reporter gene, enhanced-GFP, and were visualized and photographed using an inverted epi-fluorescence microscope (Olympus CK2; Tokyo, Japan). Upon transfection, explants were treated with or without 100 ng/ ml FGF2 for up to 5 days. The number of labeled lens epithelial cells that elongated (from up to 20 explants for each of the different treatments) were blind counted and Student's t-test was performed for statistical evaluation.
Immunofluorescent labeling of lens epithelial explants
At the end of the culture period, explants were fixed in 10% NBF for 20 min for immunofluorescent labeling as previously described (Lovicu and McAvoy, 2001) . In brief, explants were permeabilised in PBS/Tween-20, blocked with 3% normal goat serum before incubating overnight with primary antibody of interest at 4°C in a humidified chamber. On the following day, explants were rinsed with PBS and incubated with a secondary antibody at room temperature for 2 h, before counterstaining with either 67 ng/ml of propidium iodide (Invitrogen; CA, USA) for 15 min to label cell nuclei, or 30 mg/ml of TRITC-conjugated lectin (Sigma-Aldrich; Australia) for 20 min to label cell membranes. Explants were then mounted in 10% PBS in glycerol and viewed under epi-fluorescence (Leica-DMLB and Leica DC-180; Germany) or with a LSM5 Pascal confocal microscope (Carl Zeiss; USA). Primary antibodies included anti-β-crystallin (diluted 1:50), and anti-pERK1/2 (Cell Signaling Technologies, USA, diluted 1:100). Anti-rabbit Cy3 (diluted 1:200; Sigma-Aldrich; Australia), anti-mouse Alexa Fluor 594 (diluted 1:1000; Invitrogen; CA, USA), and anti-mouse Alexa Fluor 499 (diluted 1:1000; Invitrogen; CA, USA) were used as secondary antibodies.
Immunofluorescent labeling of paraffin sections
Paraffin sections were deparaffinised and hydrated as previously described (Shin et al., 2012) . Antigen retrieval was required to label for Spry1, Spry2, and pERK1/2. For this, sections were immersed in 10 mM sodium citrate buffer (pH6) and autoclaved at 121°C for 10 min, cooled to RT and immunolabeled as follows. Sections were blocked with 3% NGS before application of primary antibody overnight at 4°C in a humidified chamber. Anti-Spry1 (Santa Cruz Biotechnology; CA, USA), and anti-Spry2 (Santa Cruz Biotechnology) were diluted 1:200. Anti-pERK1/2 and anti-cleaved caspase-3 (Cell Signaling Technology; MA, USA) were diluted 1:100. Anti-βand γ-crystallins were diluted 1:50. After rinsing with PBS, slides were incubated with appropriate secondary antibodies for 2 h at RT in a dark humidified chamber. Anti-rabbit Cy3 (diluted 1:200; Sigma-Aldrich; Australia), anti-mouse Alexa Fluor 594 (diluted 1:1000; Invitrogen; CA, USA), and anti-mouse Alexa Fluor 499 (diluted 1:1000; Invitrogen; CA, USA) were used. Slides were then counterstained with 1 mg/ml bisbenzimide (Hoechst dye; Calbiochem; CA, USA) for 15 min at RT to label cell nuclei. After a final rinse in PBS, slides were mounted and viewed under epi-fluorescence (Leica-DMLB; Germany), and photographed (QCapture, QImaging; BC, Canada).
BrdU-labeling and tracking
To determine the rate of lens epithelial cell proliferation and the fate of these cells following incorporation of BrdU, P2 mice from WT, Spry1 GOF or Spry2 GOF were intraperitoneally injected with BrdU (1 mg/10 g body weight) and sacrificed after 2 h or after 7 days (at P9). Eyes were processed for paraffin embedding, and were immunolabelled for BrdU as previously described (Kallifatidis et al., 2011) . The BrdU-tagged lens epithelial cells were counted relative to total number of lens epithelial cells to determine the rate of lens cell proliferation, and the Kruskal-Wallis test was performed for statistical evaluation. Moreover, BrdU-tagged epithelial cells that had migrated posteriorly, pass the lens fulcrum (equator) into the lens fiber cortex after 7 days were also counted for each line of mice, and Student's t-test was performed for statistical evaluation.
Western blotting
Western blotting was carried out as previously described (Iyengar et al., 2006) . In brief whole lens (isolated from surrounding eye tissue) or lens explants (following treatment period) were pooled and lysed in buffer [2.5 mM EDTA, 25 mM Tris, 375 mM NaCl, 1.5 mM NaVO3, 1% (v/v) IGEPAL CA-630 (Sigma-Aldrich, Australia) and Complete mini-protease inhibitor cocktail tablet (Roche Diagnostics, Germany) in Milli-Q water]. Following centrifugation, Micro BCA protein assay reagent kit (Pierce, IL, USA) was used to determine the protein concentration of the soluble fractions. The protein samples were loaded onto SDS-PAGE acrylamide gel with a pre-stained protein molecular weights ladder (Invitrogen; CA, USA). Gels were electrophoresed and proteins transferred to PVDF membranes for blotting. Membranes were blocked with skim milk powder, and incubated with primary antibody at 4°C, overnight. Antibodies against Spry1 or Spry2 (Santa Cruz, CA, USA) were diluted 1:500. Antibodies against pERK1/2 or pAKT (Cell signaling technologies, USA) were diluted 1:2000. Those against total Erk1/2 or total Akt (Cell signaling technologies, USA) were diluted 1:1000. GAPDH (HyTest, Finland) was used as the loading control at a 1:20,000 dilution. On the following day, membranes were rinsed and incubated with the appropriate secondary antibody at RT for 2 h. For GAPDH, rabbit anti-mouse IgG conjugated to horseradish peroxidase (HRP; Zymed, CA, USA) was used at 1:10,000 dilution. For all other primary antibodies, goat anti-rabbit HRP-conjugate IgG (Cell Signaling Technologies, USA) was used at 1:5000 dilution. After rinsing, the membranes were incubated in Immobilon Western Chemiluminescent HRP Substrate (Millipore; MA, USA) for 5 min and signals were detected with Alpha Innotech FluorChem SP Imaging System (Cell Biosciences; CA, USA). For re-labeling of Western blots, the PVDF membranes were stripped with Stripping Buffer [6.25 mM Tris-HCl, 69 mM SDS, 100 mM β-mercaptoethanol in deionised water] for 20 min at 55°C. After rinsing, the membranes were once again blocked and immunolabelled as described earlier. Densitometry was used to quantify and compare the protein label of different samples on a Western blot using Alpha Innotech FluorChem SP Imaging System (Cell Biosciences; CA, USA). Student's t-test were performed for statistical evaluation.
Results

Spry overexpression in the lens
A number of different lines of transgenic mice overexpressing Spry1 in the lens were generated (LOV28, LOV29, LOV30 and LOV31), all demonstrating increased levels of Spry1 protein in the neonatal murine lens relative to the endogenous levels of Spry1 in wild type lens ( Fig. 1 ). This marked increase in Spry1 expression was confirmed using western blotting and densitometry (data not shown), with transgenic line LOV28 expressing relatively higher levels of Spry1 at postnatal day 21 (P21; 1.4-1.8 times the level of that of other Spry1 lines), hence we have used this line, referred to as Spry1 GOF , for most of the data presented. The endogenous levels of Spry1 protein in the WT neonatal lens were relatively very low ( Fig. 1B) , compared to the marked increase in levels of Spry1 in the lens epithelium and fibers of Spry1 GOF mice (Fig. 1D ). The levels of Spry2 protein in P21 transgenic mouse (Spry2 GOF ) lens was also markedly increased as determined by densitometry of western blots ( 5-fold), compared to the WT lens ( Fig. 1J ). This was confirmed using immunofluorescence for Spry2 in the neonatal lens of Spry2 GOF transgenic mice ( Fig. 1H ). Given the strong label for Spry2 in the WT lens epithelium ( Fig. 1F ), any increase in Spry2 levels in lenses of the Spry2 GOF mice was difficult to detect; however, an increase in expression of Spry2 levels was readily apparent at the transitional zone, and in early secondary fiber cells ( Fig. 1H, asterisk) .
Histology
We compared the histology of postnatal lenses from Spry1 GOF and Spry2 GOF transgenic mice lines to WT mice (or only Cre-positive lines), at postnatal ages P0, . For the purpose of this study, we only characterized transgenic mice homozygous for the Spry1 GOF transgene, as heterozygous mice did not present a phenotype (data not shown; see Shin et al. (2012) ). For the Spry2 GOF transgenic line, we characterised only lenses from animals heterozygous for both the MSGOF and Le-Cre (or MLR10-Cre; see , that presented a similar lens phenotype regardless of the Cre-recombinase line used.
A pronounced phenotype of the Spry1 GOF and Spry2 GOF transgenic mice was the smaller size of the lens, compared to the WT lens (see Figs. 2 and 3); and this was readily observed from postnatal day 0 (P0, Fig. 2B and C), P5 ( Fig. 3C and E) and P10 ( Fig. 3D and F) , consistent with the fact eyes were microphthalmic. From postnatal day 0, at higher magnification, we note only subtle changes in the epithelia of the Spry1 GOF and Spry2 GOF transgenic mice lenses, when compared to the WT lenses ( Fig. 2G -I). One of the initial changes observed in the Spry1 GOF and Spry2 GOF lenses at this age was a modest reduction in height of the central epithelial cells ( Fig. 2H and I). This diminished cell height was also noticeable in the peripheral lens epithelium of the Spry2 GOF lens (Fig. 2L ) but not so much in the Spry1 GOF lens (Fig. 2K) , when compared to the WT lens ( Fig. 2J ). Early secondary lens fiber cell differentiation was also somewhat compromised at P0, more prominently in the Spry2 GOF mice that lacked an ordered lens bow region, based on the irregular displacement and positioning of the secondary lens fiber cell nuclei ( Fig. 2F and L) , compared to the WT and Spry1 GOF mice ( Fig. 2D , E, J and K).
By P5 (Figs. 3 and 4), the early secondary fibers of the Spry2 GOF lens appeared fewer in number (fewer cell nuclei) and were still not arranged in a coordinated manner (Figs. 3E and 4F) as seen in the bow region of the WT and Spry1 GOF lens (Figs. 3A, C and 4D, E). Moreover, there were prominent irregular-shaped acellular vacuoles in the lens cortex of the Spry2 GOF mice, that further disrupted the alignment of the secondary lens fiber cells (Figs. 3E and 4F). As the lens matured at P5, the central epithelial cell height reduction in the Spry1 GOF and Spry2 GOF ( Fig. 4B and C) lines was more pronounced, supported by cell nuclei adopting a more flattened shape. This thinning epithelia persisted at P10 (data not shown), with a significantly thinner lens epithelium in the Spry2 GOF (9.07 0.6 mm) lens, but not Spry1 GOF (10.0 71.0 mm) lens, compared to the WT lens (13 71.0 mm; Student's t-test; n ¼8; Spry1 GOF p 40.07, Spry2 GOF p o0.002). At P5 and P10, the peripheral epithelium of the Spry2 GOF lens (see Fig. 4F ) was also thinner than the WT lens epithelium (Fig. 4D) ; however, the peripheral epithelium of the Spry1 GOF lines (Fig. 4E ) appeared similar in thickness to that of the WT lens ( Fig. 4D ).
Common to both Spry1 GOF and Spry2 GOF transgenic mice lenses was the rupture of the posterior lens capsule by P10 ( Fig. 3D and F, arrowheads). Unique to the Spry1 GOF lens; however, was the displacement of the transitional zone at P10, with lens epithelia extending more posteriorly (Fig. 3D , arrows, 3D′). The multiple irregular, acellular vacuoles in the lens fiber cortex of the Spry2 GOF lens also persisted at P10 ( Fig. 3 ) and were further exacerbated by P21 (data not shown). These cortical vacuoles present in the Spry2 GOF line were also observed at P21 in the Spry1 GOF line but were not as severe (data not shown).
Lens capsule modification
Given that the lens of both the Spry1 GOF and Spry2 GOF lines rupture by P10 ( Fig. 3) , we examined for changes in the thickness of both the anterior and posterior lens capsule with age. At P0 ( Fig. 5A -F) and P5 ( Fig. 5G-M) , the anterior capsule of both Spry1 GOF and Spry2 GOF lenses were similar in thickness to that of the WT lens (compare Fig. 5A , C, E and G, J, L). By P10, the anterior lens capsule of the Spry1 GOF lens (Fig. 5P ), appeared thicker (3.970.3 mm) than that of the WT lens (3.6 mm 70.4; see Fig. 5N ), at the time of posterior lens capsule rupture ( Fig. 5Q ), but this was not significant (Student's t-test; n ¼18; p4 0.5). In contrast, the anterior lens capsule of the Spry2 GOF lens at P10 ( Fig. 5R ) was significantly thinner (2.1 70.1 mm; Student's t-test; n ¼18; po 0.0003) than that of the WT lens ( Fig. 5N ), persisting at P21 (data not shown). The posterior lens capsule of both Spry1 GOF and Spry2 GOF lenses at P0 ( Fig. 5D and F), similar to the anterior lens capsule, appeared normal in thickness compared to the WT lenses ( Fig. 5B ). At P5, the thinning of the posterior lens capsule of the Spry1 GOF line was evident ( Fig. 5K ), whilst the Spry2 GOF posterior lens capsule appeared relatively normal ( Fig. 5M ). By P10, the Fig. 1 . Elevated expression of Spry1 and Spry2 in neonatal (P0) lens of Spry1 GOF and Spry2 GOF transgenic mice. Compared to the relatively low levels of Spry1 detected in the WT lens (A, B), Spry1 protein levels are markedly higher in lenses of Spry1 GOF mice (C, D). The levels of Spry2 protein in Spry2 GOF transgenic mouse are also elevated, in particular at the transitional zone and in cortical fibers (G, H, asterisk), compared to WT lens levels (E, F), consistent with western blotting analysis of the P21 lenses (J; LC, protein loading control). Scale bar, 50 mm.
posterior lens capsule of both Spry1 GOF and Spry2 GOF lines had thinned and ruptured ( Fig. 5Q and S) , leading to the extrusion of the lens fiber content into the vitreous chamber (see Fig. 3 ).
To determine whether a reduction in PI3K-signaling in lens cells could compromise the maintenance of lens capsule, we used a selective phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) on rat lens epithelial explants treated with or without FGF, as previously described (Iyengar et al., 2007; Wang et al., 2009) . We show that PI3K-signaling is required for new lens capsule synthesis in vitro, evident by a band of differentially stained newly deposited extracellular matrix ( Fig. 6A -D, arrows). Explants pre-treated with the PI3K-inhibitor displayed a significantly (Student's t-test; n ¼14; p o0.0001) thinner lens capsule (3.77 0.2 mm) to those not treated (only DMSO-treated) with the inhibitor (4.8 70.8 mm) after 5 days culture with FGF. Similar changes in thickness were noted with control explants (no growth factor treatment) in the absence (only DMSO-treated, 4.7 70.2 mm) or presence (3.8 70.4 mm) of LY294002. The thinner capsule in explants treated with inhibitor ( Fig. 6B and D) was due to the absence of the inner layer of newly synthesized lens capsule material ( Fig. 6A and C, arrows), consistent with a role for PI3Ksignaling in protein synthesis and basement membrane formation (see Li et al. (2001a Li et al. ( , 2001b , Engelman et al. (2006) ). Interestingly, in the presence of LY294002, lens epithelial cells also appeared less cuboidal as they flattened and spread over the lens capsule (see Fig. 6B and D). To determine whether overexpression of Spry potentially led to reduced PI3K-signaling in lens, hence reduced capsule synthesis and subsequent rupture, we used western blotting to compare the levels of phosphorylated Akt (pAkt) in lenses of both Spry1 GOF and Spry2 GOF with WT lens (Fig. 6E ). In lenses of P7 mice, before lens capsule rupture, whilst there appeared to be slightly lower levels for pAkt in the Spry1 GOF and Spry2 GOF lenses compared to that of the WT lens ( Fig. 6E) , this was not a significant difference. Both pAkt and total Akt levels were corrected for the GAPDH levels with the ratio of pAkt against total Akt levels in the WT lens set to equal 1. The ratio obtained from the transgenic lenses compared to WT, was 0.89 and 0.97 for Spry1 GOF and Spry2 GOF , respectively ( Fig. 6F) , not significantly different from that of the WT lens (student's t-test; Spry1 GOF p 40.1; Spry2 GOF p 40.4).
Lens fiber differentiation
The histology of the transgenic lenses demonstrated a prominent defect in lens fiber differentiation, prior to disruption of the lens epithelium and also prior to lens rupture, especially in mice overexpressing Spry2 (Spry2 GOF ; Fig. 3 ). Immunolabeling for βcrystallin in neonatal WT, Spry1 GOF and Spry2 GOF lenses demonstrated normal patterns of β-( Fig. 7) and γ-crystallin (data not shown) accumulation. Irrespective of this, the resultant transgenic lenses were smaller in size, questioning whether lens cells overexpressing Spry were compromised in their ability to respond normally to fiber differentiation stimuli. To test this, epithelial explants prepared from lenses of WT, Spry1 GOF and Spry2 GOF mice were cultured for up to 10 days with a fiber-differentiating dose of FGF2 ( Fig. 8 ). Using lectin staining to demonstrate differences in cell shape changes, consistent with the in situ data, we observed that lens cells overexpressing Spry2 (Spry2 GOF ) did not effectively elongate and differentiate into fiber cells ( Fig. 8J and K) , unlike lens cells from WT and Spry1 GOF mice that elongated in response to FGF ( Fig. 8A, B , E and F). These lens explant tissues all expressed increased levels of β-crystallin when treated with FGF after 10 days (data not shown); however, there were more pronounced differences in their ability to accumulate β-crystallin by 5 days culture. After 5 days culture, there were fewer β-crystallin-labeled cells in FGF-treated lens explants prepared from the Spry1 GOF (Fig. 8H , arrows) and Spry2 GOF (Fig. 8M , arrows) mouse lines, compared to WT lens (Fig. 8D, arrows) , indicating a delayed and impaired differentiation response to FGF.
To further support that overexpression of Spry1 or Spry2 in lens Fig. 3 . Representative H&E staining of WT mice lens, and Spry1 GOF and Spry2 GOF transgenic mice lens. The lenses of WT (A,B), and Spry1 GOF (C,D) and Spry2 GOF (E, F) transgenic mice lines were compared at P5 (A, C, E) and P10 (B, D, F). At P5, smaller-sized lenses were noted for both Spry1 GOF and Spry2 GOF transgenic mice with posterior lens capsule rupture (arrowheads) of lenses by P10. In the Spry1 GOF lens, the transitional and bow zones (arrows) were located far more posterior to the lens equator (shown at higher magnification, D′), than that seen in WT lens. In the Spry2 GOF lens, there were irregular, acellular vacuoles present in the lens fiber cortex (*). Furthermore, in the Spry2 GOF lens, the denucleation in the early secondary fibers appeared disorganized. Scale bar, A-F, 200 mm; D′, 100 mm.
cells impacts directly on FGF2-induced fiber cell differentiation, we transfected cells in rat lens epithelial explants to overexpress Spry1 or Spry2 (Fig. 9 ). Spry cDNA was inserted into the pLXSG vector containing an enhanced green fluorescent protein (EGFP)
reporter gene, to generate pLXSG-Spry1 or pLXSG-Spry2. Without any growth factor treatment, lens epithelial cells transfected with pLXSG, pLXSG-Spry1 or pLXSG-Spry2 remained as cuboidal epithelial cells after 5 days of culture ( Fig. 9A , C, and E). Once these transfected cells were treated with a differentiating dose of FGF2 for 5 days, most lens epithelial cells transfected with pLXSG elongated ( Fig. 9B and G) . In comparison, a substantial sub-population of cells transfected with pLXSG-Spry1 or pLXSG-Spry2 did not elongate ( Fig. 9D , F, and G). The percentage of cells transfected with pLXSG, pLXSG-Spry1 and pLXSG-Spry2 that underwent cell elongation was recorded as 63.7%, 31.9% and 32.9%, respectively (Fig. 9G ), a significant reduction in FGF-induced fiber cell elongation with either pLXSG-Spry1 or pLXSG-Spry2 (Student's t-test; p o0.005).
The specificity of pLXSG-Spry2 is highlighted by similar experiments replacing the intact Spry2 cDNA with a mutated form of Spry (ΔSpry), where cells retained their ability to elongate in response to FGF (Fig. 10H ), similar to cells not overexpressing Spry2 (Fig. 10B ). Cells overexpressing Spry2 (pLXSG-Spry2) had impaired FGF-induced fiber cell elongation/differentiation (Fig. 10F) , similar to when a dominant negative FGFR1 was overexpressed to block FGFR-signaling ( Fig. 10D) .
Lens epithelial cell proliferation
Whilst impaired fiber cell differentiation may contribute to the smaller lens size in Spry1 GOF and Spry2 GOF mice, we examined other cellular processes required for lens growth, including lens epithelial cell proliferation. We first compared the number of lens epithelial cells in sequential mid-sagittal lens sections from WT, Spry1 GOF and Spry2 GOF mice (Fig. 11A ). Compared to the WT lens epithelium at different postnatal stages (P2, P4, and P9), the size of Fig. 4 . Representative H&E staining of WT mice lens, and Spry1 GOF and Spry2 GOF transgenic mice lens at P5 (A-F). At P5, the central lens epithelial cells of the Spry1 GOF (B, E), and Spry2 GOF (C, F) transgenic mice lines had markedly reduced cell height, compared to that of the WT lens (A, D). Apart from this, the Spry1 GOF lens appeared similar to the WT lens. In the Spry2 GOF line, the diminished cell height was also observed in the peripheral lens epithelium (F), together with irregularshaped, acellular vacuoles (*) in the lens fiber cortex. Scale bar, 50 mm. Fig. 5 . PAS staining of the lens capsule of WT mice, and Spry1 GOF (S1) and Spry2 GOF (S2) transgenic mice lens, at P0 (A-F), P5 (G-M) and P10 (N-S). When the anterior lens capsule (left panels) of the Spry1 GOF (C, J, P) and Spry2 GOF (E, L, R) transgenic mice were compared to that of WT (A, G, N), the Spry1 GOF lens capsule appeared similar in thickness to the WT lens at P0 and P5, but slightly thicker at P10, albeit not significantly different (Spry1 GOF lens, 3.9 7 0.3 mm; WT lens, 3.6 7 0.4 mm). The anterior capsule of Spry2 GOF lens (R); however, was significantly thinner (2.17 0.1 mm; Student's t-test; n¼ 18; po 0.0003) than that of the WT lens (N) at P10. The posterior lens capsule (right panels) of WT mice (B, H, O), and Spry1 GOF (D, K, Q) and Spry2 GOF (F, M, S) transgenic mice lens were of similar thickness at P0; however, at P5, the posterior capsule of Spry1 GOF lenses was thinner than that of the WT and Spry2 GOF ; however, by P10, both posterior capsules of Spry1 GOF and Spry2 GOF lenses ruptured (Q, S). Scale bar, 30 mm.
the epithelium based on average cell numbers, was significantly smaller for all ages of Spry1 GOF and Spry2 GOF mice (student's ttest; p o0.0005). In WT mice, cell numbers increased in number from 143 (P2) to 193 (P4) to 200 (P9), compared to similar increases, albeit reduced cell numbers, for both Spry1 GOF (127, 161, and 186) and Spry2 GOF (97, 125, and 128) mice, respectively (Fig. 11A ). This reduced cell number was not a result of increased cell death/apoptosis (as determined by the absence of any cleaved-caspase-3-labeling; data not shown), but by a reduced rate of epithelial cell proliferation. The percentage of BrdU-labeled cells in the WT, Spry1 GOF and Spry2 GOF P2 lens was progressively lower (21.9%, 20.4% and 18.5%, respectively, Fig. 11B) , with the greatest and most significant difference in proliferation rate between the WT and Spry2 GOF lens (Kruskal-Wallis test; po 0.005). The rate of epithelial cell proliferation in the whole epithelium of the Spry1 GOF lens was not significantly different to that of the WT lens (Kruskal-Wallis test; p4 0.05); however, if we compared the central and peripheral regions of the epithelium, there were marked differences between the Spry1 GOF and WT lens (Fig. 11C) . The rate of proliferation in the central epithelium of the Spry1 GOF lens (12.1%) was significantly lower than that of the WT central lens epithelium (19.4%; Kruskal-Wallis test; po 0.005). In contrast, the proliferation rates of the peripheral epithelium of the WT lens (25.1%) and Spry1 GOF lens (27.7%), did not markedly differ (Fig. 11C) . The combination of the data of the central and peripheral epithelial cell proliferation rates results in the previously observed insignificant difference in total epithelial cell proliferation rate between the WT lens and Spry1 GOF lens. For completeness, the central and peripheral lens epithelium of WT and Spry2 GOF were also compared, with a significant decrease only observed between their peripheral epithelia (19.4% and 11.9%; Kruskal-Wallis test; po0.005) and not their central epithelia (25.1% and 23.6%, respectively; data not shown).
It should be noted that the lens epithelial cell phenotype in the Spry2 GOF lens was specifically due to overexpression of Spry in the lens epithelia and not extra-lenticular overexpression. When we characterized alternate Spry2 GOF lines with Spry2 overexpressed specifically to the lens cells (using a different Cre-transgenic line; MLR10-Cre), we saw no significant difference at E15.5 in lens epithelial cell number or rate of cell proliferation relative to agematched WT lens (data not shown).
Rate of lens fiber cell differentiation
To determine the rate of lens epithelial cell differentiation into fibers, BrdU-labeled cells were traced for 7 days at P9, after BrdU incorporation at age P2. This study has the underlying principle that BrdU-incorporation in nuclei of proliferating lens epithelial cells will persist as they or their progenitors are displaced into the lens cortex as they exit the cell cycle and differentiate into secondary fiber cells (Fig. 12 ). In the WT, Spry1 GOF and Spry2 GOF lens fiber cortex sections, an average of 23, 21 and 11 BrdU-labeled cells were detected after 7 days, respectively (Fig. 12D ). Compared to the WT lens ( Fig. 12A and D) , the number of BrdU-labeled cells in the lens cortex sections of the Spry2 GOF lens (Fig. 12C and D) was significantly reduced (student's t-test; p o0.0005), while the Spry1 GOF transgenic lens sections showed no significant difference in labeled cell number ( Fig. 12B and D) . and GAPDH (loading control; lower panel) from P7, WT mice, and Spry1 GOF and Spry2 GOF transgenic mice, showed that levels of pAkt appeared lower in the transgenic lenses, however, relative to total Akt and GAPDH levels, the pAkt levels between genotypes was not significant (F; student's t-test: Spry1 GOF p 40.1; Spry2 GOF p 40.4. Error bars represent standard errors).
Regulation of ERK1/2 phosphorylation by Spry1 and Spry2
The endogenous levels of phosphorylated ERK1/2 and total ERK1/2 in P21, WT mice lens, and age-matched Spry1 GOF and Spry2 GOF transgenic mice lens were assayed using western blotting (Fig. 13 ). The representative western blots showed that Spry1 GOF and Spry2 GOF lens have lower levels of pERK1/2, compared to that of the WT lens ( Fig. 13A ). Quantitative analysis of the western blots showed that when the ratio of pERK1/2 to total ERK1/2 in the WT lens was standardized to a value of 1, the relative levels of pERK1/2 in the transgenic lenses were significantly lower (student's t-test; p o0.0005), recorded as 0.35 and 0.71 for Spry1 GOF and Spry2 GOF lenses, respectively (Fig. 13B) . Given that the total ERK1/2 levels across the different genotypes was not equal, we used GAPDH levels to standardize the western blots against the total ERK1/2 levels. The cells of the Spry1 GOF and Spry2 GOF transgenic lenses were shown to express significantly higher levels of total ERK1/2, than those of the WT lens (student's t-test; Spry1 GOF po 0.0005; Spry2 GOF p o0.005), recorded as 1.47 and 1.15 for Spry1 GOF and Spry2 GOF lenses, respectively (Fig. 13C) . Thus, when the pERK1/2, total ERK1/2 and GAPDH levels are considered together, it appears that the Spry1 GOF and Spry2 GOF transgenic mice lens cells have higher levels of total ERK1/2, but the levels of phosphorylated ERK1/2 are lower when compared to the WT lens cells. Immunofluorescence on neonatal WT, Spry1 GOF and Spry2 GOF transgenic mice lenses show a consistent decrease in label of pERK1/2 in Spry1 GOF and Spry2 GOF mice (data not shown).
We demonstrate above that lens-specific overexpression of Spry1 or Spry2 in situ resulted in a decreased pool of phosphorylated ERK1/2 and an increased level of total ERK1/2 in the lens. To determine the ability of these same cells to phosphorylate ERK1/2 in response to exogenous factors in vitro, we prepared lens epithelial explants from postnatal-day-7 WT, Spry1 GOF and Spry2 GOF mice and determined the responsiveness of cells to different doses of FGF2 ( Fig. 14) and EGF (Fig. 15 ) for up to 20 min. With no growth factor addition, the central epithelial cells of the WT lens, and Spry1 GOF and Spry2 GOF transgenic lenses all had very similar low basal pERK1/2 labeling (Figs. 14A-C and 15A-C). With a relatively low (5 ng/ml) proliferating dose of FGF2, some isolated epithelial cells of the WT lens, and Spry1 GOF and Spry2 GOF lenses expressed higher levels of pERK1/2 ( Fig. 14D-F, arrows) . The pERK levels; however, appeared higher in cells of the WT lens explants. When the dose of FGF-2 was increased (50 ng/ml), the greatest difference in ERK1/2 phosphorylation was now observed between the WT and transgenic lens explants with ERK1/2 phosphorylation homogenously observed across the entire WT lens explant (Fig. 14G) . The explants of the Spry1 GOF and Spry2 GOF lenses ( Fig. 14H and I) showed increased pERK labeling, albeit at markedly lower levels compared to the WT lens explants. Moreover, labeling for pERK in the transgenic lens epithelial cells was not homogenous across the explants, with select cells demonstrating higher pERK1/2 levels. With an even higher (100 ng/ml), differentiating dose of FGF2, there was saturation of ERK1/2 phosphorylation in the WT lens explants, with all epithelial cells demonstrating high pERK1/2 levels (Fig. 14J) . The Spry1 GOF and Spry2 GOF lens explants also showed high levels of ERK1/2 phosphorylation ( Fig. 15K and L) , closely resembling the WT lens pERK1/2 levels; however, there were isolated cells that demonstrated little to no pERK1/2 labeling ( Fig. 14K and L, arrowheads) .
Experiments with EGF demonstrated a similar result to that seen with FGF. With 50 ng/ml of EGF, isolated central epithelial cells of the WT lens showed markedly elevated phosphorylation of ERK1/2 (Fig. 15D) . The lens cells of the Spry1 GOF and Spry2 GOF explants, under the same treatment conditions, also demonstrated an increased ERK1/2 phosphorylation ( Fig. 15E and F) ; however, much lower than that of the WT cells. At higher doses (100 ng/ml) of EGF, a greater number of epithelial cells responded, with ERK1/2 phosphorylation increasing in all lens explants ( Fig. 15G-I) ; however, the levels of ERK1/2 phosphorylation in the epithelial cells of both Spry1 GOF and Spry2 GOF transgenic lenses was still lower than that of the WT lens. Overall, lens epithelial cells of the Spry1 GOF and Spry2 GOF transgenic mice demonstrated a reduced ability to phosphorylate ERK1/2 in response to FGF2 and EGF. The FGF2-or EGF-induced phosphorylation of ERK1/2 was dose-dependent, with intermediate (50 ng/ml) doses of both FGF-2 and EGF showing the greatest differences between lenses of WT and the Spry GOF mice. Interestingly, this in vitro assay also demonstrated that FGF-2 stimulation results in a more homogenous ERK1/2 Fig. 8 . Representative micrographs of lens epithelial explants from P7, WT mice (A-D), or Spry1 GOF (E-H) and Spry2 GOF (J-M) transgenic mice lenses, treated with 100 ng/ml of FGF2 (right hand panels) or without (left hand panels) for either 5 days (C, D, G, H, L, and M) or 10 days (A, B, E, F, J, and K). Tissues were stained for lectin (A, B, E, F, J, and K, purple), β-crystallin (D, H, and M, green) and counterstained with propidium iodide (C, G, and L, red). The lectin stain outlines cell membranes, highlighting organelles and cell shape changes. In response to FGF2, WT lens epithelial cells underwent elongation (B) and accumulated β-crystallin (D). Epithelial cells of the Spry1 GOF lens explants also elongated (F) with FGF2 treatment (D) with little β-crystallin accumulation by 5 days (H). In contrast, in Spry2 GOF transgenic mice lens explants, cells showed little to no differentiation (K) in response to FGF2, with no β-crystallin detected (M). Scale bar, 10 mm. phosphorylation response throughout the lens explant, whereas EGF-induced ERK1/2 phosphorylation was limited to a subset of the lens explant cell population.
It should be noted that while the higher expression levels of Spry1 in the LOV28 transgenic line resulted in a prominent phenotype, the other characterized Spry1 lines presented a similar phenotype (data not shown), with microphthalmia and smaller lenses, and a similar reduction in height of lens epithelia and reduced thickness of lens capsule, validating the specificity of the effect of Spry1 overexpression.
Discussion
In the present study we demonstrate an important inhibitory role for Spry in the regulation of lens cell proliferation and fiber differentiation in situ, potentially through its ability to modulate FGF-and even EGF-mediated MAPK/ERK1/2 signaling in lens cells. Overexpression of Spry in the lens epithelial and fiber cells resulted in reduced lens size during ocular morphogenesis, influenced by changes to the lens epithelium, aberrant fiber cell differentiation and compromised de novo maintenance of the lens capsule. Given the fact that Spry is normally highly expressed throughout lens morphogenesis in both differentiating lens epithelium and primary fiber cells, with reduced expression in fibers during fetal and postnatal growth (see Boros et al. (2006) ), it is not surprising that overexpression of Spry1 or Spry2 in lens in the present study has a marked impact on lens differentiation later in its development and growth.
Spry negatively regulates lens epithelial cell proliferation
Overexpression of Spry in the lens epithelium led to pronounced changes such as progressively reduced cell numbers and some thinning of the epithelium, similar to that seen in lenses of mice deficient for a known Sprouty target, MAPK1/ERK2 (Upadhya et al., 2013) . Earlier conditional deletion studies of both Spry1 and Spry2 in the developing lens do not report any changes to lens epithelial cell proliferation at E15.5 (Kuracha et al., 2011) , most likely owing to the fact that there are other negative regulators, including members of the Spred family co-expressed in the lens (Zhao et al., 2015) that may compensate for this loss of Sprouty at this time. In contrast, in the present study with Spry1 GOF and Spry2 GOF transgenic mice lenses, there was a significant reduction in epithelial cell proliferation when Spry was overexpressed. In the Spry1 GOF lens, this was most evident in the central lens epithelium. This reduced epithelial cell proliferation correlated with the reduced number of lens epithelial cells in both the Spry1 GOF and Spry2 GOF transgenic mice, compared to that of WT mice. This is consistent with the reported role of Spry1, Spry2 and even Spry4 as anti-proliferative regulators of serum or growth factor-(EGF, FGF, PDGF, VEGF, and HGF) induced DNA synthesis/cell proliferation (Edwin et al., 2006; Gross et al., 2001; Lee et al., 2004 Lee et al., , 2001 Yigzaw et al., 2001) . In human umbilical vein endothelial cells, it is suggested that Spry induces cell cycle arrest and not cell death (Lee et al., 2001) , consistent with our observations. hSpry2 overexpression in SK-LMS-1 human leiomyosarcoma cells also resulted in cell cycle arrest at the G2/M phase (Lee et al., 2004) , suggesting Spry2 prevents cells from re-entering the G1 phase. Moreover, ectopic hSpry2 expression can decrease cell cycle progression from the G1 to S phase (Edwin et al., 2006) , consistent with an elevation in the expression and activity of PTEN (phosphatase and tensin homolog deleted on chromosome 10). PTEN has been shown to cause cell cycle arrest in the G1 phase (Li and Sun, 1998) and is known to suppress PI3K/Akt-signaling (Cantley and Neel, 1999) . Taken together with Spry's reported inability to inhibit proliferation and suppress PI3K/Akt-signaling in PTEN-deficient cells Fig. 9 . Representative micrographs of neonatal rat lens epithelial cells transfected with pLXSG (A, B) , pLXSG-Spry1 (C, D) or pLXSG-Spry2 (E, F), and treated with (right panels) or without (left panels) a differentiating dose (100 ng/ml) of FGF2 for 5 days. All successfully transfected cells fluoresce green for the EGFP reporter. The control lens epithelial cells transfected with either pLXSG, or overexpressing Spry1 (pLXSG-Spry1) or Spry2 (pLXSG-Spry2) with no growth factor treatment remained cuboidal in shape (A, C, and E). With FGF2 treatment, lens epithelial cells transfected with the control pLXSG plasmid changed their morphology and began to elongate. A subpopulation of the lens epithelial cells transfected with pLXSG-Spry1 or pLXSG-Spry2, however, did not elongate (D, F, arrows). Scale bar, 100 mm. (G) Quantitative analysis of the percentage of the FGF2-induced lens epithelial cell elongation showed that with FGF2 treatment, there were 63.7%, 31.9% and 32.9% elongation among the cells transfected with pLXSG, pLXSG-Spry1 and pLXSG-Spry2, respectively. Spry1 or Spry2 overexpression in lens epithelial cells in vitro, demonstrated a significant reduction in FGF2-induced cell elongation (n¼ 5, Student's t-test; p o 0.005). (Edwin et al., 2006) , in the lens, Spry may play a role in the regulation of cell cycle progression partially through the actions of PTEN, and regulation of Akt phosphorylation. Whilst we observed slightly lower, albeit not significant levels of pAkt in whole postnatal Spry GOF transgenic mice lenses, we can not rule out reduced levels of pAkt specifically in the lens epithelia, hence a role for PI3K-signaling in cell proliferation, consistent with our earlier studies (Iyengar et al., 2006) . This is supported by hSpry2's ability to decrease EGF-or serum-induced Akt phosphorylation (Edwin et al., 2006) . As other studies in different cell types have shown that Spry does not affect the PI3K/Akt pathway (Gross et al., 2001; Yusoff et al., 2002) , Sprys' negative regulation of ERK1/2 signaling may play a more significant role in suppressing lens cell proliferation in our in vivo study, consistent with other in situ studies in lenses deficient for MAPK1 (Upadhya et al., 2013) , as well as our previous in vitro studies using MEK1 inhibition (Iyengar et al., 2006 (Iyengar et al., , 2009 . Our future studies are aimed to develop more effective means of specifically identifying the direct targets of Sprouty activity in lens cells.
Spry negatively regulates lens fiber cell differentiation
Our in vivo observations demonstrate that overexpression of either Spry1 or Spry2 in the lens results in a 'small' lens phenotype. While this may be a compound phenotype resulting from reduced cell numbers as discussed earlier, it is evident that this smaller lens may also result from compromised lens fiber cell differentiation, resulting in shorter, yet still elongate fiber cells. We should note that the primary fiber cell phenotype is directly due to overexpression of Sprouty in situ, and not a secondary effect relating to changes in the lens epithelium, given that at earlier neonatal stages when we see a fiber cell phenotype, the lens epithelial cells appear relatively normal. Moreover, in Spry GOF mice, in particular the Spry2 GOF mice, the rate of epithelial cells differentiating into fibers is markedly reduced and when epithelial cells do manage to differentiate into fibers, the fiber cell nuclei are poorly arranged compared to WT lens, with fibers cells appearing disorganized and vacuolated, comparable to lenses of mice deficient for ERK2 (Upadhya et al., 2013) . Interestingly these fiber cells still express ß-and γ-crystallins; however, we should be mindful that expression of these molecular markers of fiber differentiation have been show not to be dependent on ERK1/2 signaling (see Lovicu and McAvoy 2001; Wang et al., 2010; Upadhya et al., 2013) , which appears to be the likely target of Sprouty in these trangenic lenses resulting in the morphologic phenotype.
Sprouty's ability to negatively regulate fiber differentiation in situ is further supported by our in vitro evidence using lens epithelial cell explants from transgenic mice overexpressing Spry1 or Spry2; their compromised ability to respond to differentiationstimuli (such as FGF2). This was independently supported by further in vitro experiments, whereby ectopic overexpression of Spry1 or Spry2 in rat lens epithelial cells was sufficient to block a significant subpopulation of epithelial cells from undergoing FGF2induced fiber cell differentiation. This ability of both Spry1 or Spry2 to impede FGF2-induced activity in lens was also similarly observed in PC12 cells (Gross et al., 2001) . Murine Spry1 and Spry2 overexpression in PC12 cells resulted in reduced FGF-or NGF-induced cell differentiation, with the cells developing shorter and reduced branching of neurites (Gross et al., 2001) . We should note that not all lens cells overexpressing Spry1 or Spry2 were able to completely block lens fiber differentiation in vitro, consistent with the presence of relatively normal lens fiber cells in the Spry1 GOF and Spry2 GOF transgenic mice. This clearly indicates that the suppressive effects of Spry may be dose-dependent, consistent with the fact that mice hemizygous for Spry1 gain of function (Shin et al., 2012) develop a relatively normal lens compared to the homozygous lines reported here. Sprouty gene dosage has also recently been reported to be required for temporal-spatial supernumerary tooth formation (Lochovska et al., 2015) .
Whilst Spry overexpression has the potential to impair lens fiber differentiation, it may also influence the rate of epithelial cell-to-fiber differentiation, as we report here. By tagging proliferative lens epithelial cell nuclei in situ following BrdU-incorporation, and monitoring the fate of these cells after a defined period, we noted that the number of Spry2 GOF lens epithelial cells entering the lens cortex and subsequently differentiating, were fewer in number resulting in the fewer secondary fibers in the lens cortex compared to the lens of WT or Spry1-overexpressing mice, similar to that seen in lenses of mice deficient for ERK2 (Upadhya et al., 2013) . This was not necessarily a reflection of reduced epithelial cell numbers in transgenic mice to start with, as a similar percentage of epithelial cells were BrdU-labeled at the lens periphery in all groups of animals examined. Whether this fiber differentiation process is delayed or is a consequence of impaired cell migration is not clear and merits further investigation. Indeed in other studies in rat intestinal epithelia (IEC-6 cells), Spry2 inhibited migratory activity by inhibiting Rac1 activation (Poppleton et al., 2004) . Rac1 GTPase activity clearly has been shown to play an essential role not only in lens fiber cell migration (Maddala et al., 2011) but also ECM turnover (see later Section 4).
Interestingly, a slight increase in the proliferation rate of peripheral lens epithelial cells, coupled with a slightly decreased rate of fiber cell differentiation in the Spry1 GOF lens, compared to the Fig. 11 . (A) Quantitative analysis of the total number of epithelial cells in sections of WT lens, and Spry1 GOF and Spry2 GOF transgenic lenses at P2, P4 and P9. The average number of epithelial cells in a section of WT lens were 143, 193 and 200 for ages P2, P4 and P9, respectively. The average number of epithelial cells in sections of Spry1 GOF transgenic mice lens were 127, 161 and 186 for ages P2, P4 and P9, respectively. The average number of epithelial cells in sections of Spry2 GOF transgenic mice lens were 97, 125 and 128 for ages P2, P4 and P9, respectively. At P2, the size of the lens epithelium of both Spry1 GOF and Spry2 GOF transgenic lines was significantly smaller than the WT lens epithelium size (Student's t-test; p o0.0005). This trend was also observed at P4 (Student's t-test; p o 0.0005) and P9 (Student's t-test; p o0.0005). Error bars represent standard errors. (B) Quantitative analysis of the percentage of BrdU-incorporation in lens epithelial cells of WT mice, and Spry1 GOF and Spry2 GOF transgenic mice at P2. Blind counts showed 21.9%, 20.4% and 18.5% of epithelial cells labeled for BrdU in WT, Spry1 GOF and Spry2 GOF lenses, respectively. The proliferation rate of Spry2 GOF transgenic lens epithelial cells was significantly lower than that of WT lens (Kruskal-Wallis test T ¼12.76; n¼ 54; p ¼ 0.0018). The proliferation rate of Spry1 GOF transgenic lens epithelial cells showed no significant difference compared to that of WT lens (Kruskal-Wallis test T ¼12.76; n¼ 54; p ¼0.1684). Error bars represent standard errors. (C) Quantitative analysis of the percentage of BrdU-incorporation in the more central anterior and peripheral lens epithelial cells of WT lens and Spry1 GOF transgenic lens. For the central lens epithelium, cell proliferation rates were 19.4% and 12.1% for the WT lens and Spry1 GOF lens, respectively, significantly lower in the Spry1 GOF transgenic lens (Kruskal-Wallis test T ¼ 13.96; n¼ 54; p ¼ 0.001). For the peripheral lens epithelium, the cell proliferation rates were 25.1% and 27.7% for the WT lens and Spry1 GOF lens, respectively, with no significant difference in rate of proliferation (Kruskal-Wallis test T¼ 5.35; n¼ 54; p ¼ 0.337). Error bars represent standard errors.
WT, may explain why fiber cell differentiation occurred more posterior to the lens equator. More lens epithelial cells were mitotic in the Spry1 GOF lens, and less of their progeny were exiting the cell cycle to become lens fibers. In addition, the size of the Spry1 GOF lens was smaller compared to the WT lens due to insufficient numbers of fibers, and perturbed elongation of these cells.
Overall, Spry1 and Spry2 were able to inhibit/impair both lens cell proliferation and fiber differentiation, which share some similar signaling pathways and regulators (see Lovicu and McAvoy, 2001; Iyengar et al., 2007) . This inhibitory effect of Spry and the resultant cell fate may also depend on the cellular context. For example in human leiomyosarcoma cells, cell movement is restricted by hSpry2 by facilitating cell attachment and spreading through enhancement of focal adhesions (in particular vinculin) and increased expression of stress fibers (in particular F-actin; Lee et al. (2004) ). This promotion of cell spreading, coupled with the decreased central lens epithelial cell proliferation rate, may in part also account for the thinner lens epithelium observed in our Spry2 GOF transgenic lines.
Spry negatively regulates FGF-and EGF-induced ERK1/2 signaling
Whilst there may be several contributing factors accounting for the reduced size of the lens in the Spry1 GOF and Spry2 GOF transgenic mice, in order to understand the molecular mechanisms leading to the Spry-mediated suppression of lens epithelial cell proliferation and differentiation, we examined one of its direct targets, ERK1/2 signaling. In situ overexpression of Spry in transgenic mice lenses, led to a reduction in endogenous ERK1/2 phosphorylation in both the lens epithelial and fiber cells of the Spry1 GOF and Spry2 GOF transgenic mice. Not surprisingly, as mentioned earlier, the postnatal lens phenotype we report here, in particular that seen in Spry2 GOF transgenic mice, is very similar to recent reports of the phenotype of postnatal lenses deficient for MAPK1/ERK2 (Upadhya et al., 2013) . Moreover, in our in vitro studies we demonstrated that these lens epithelial cells overexpressing Spry1 or Spry2 have a reduced ability to phosphorylate ERK1/2 in response to either FGF and EGF, and this was dose-dependent. Overexpression of Spry has been previously demonstrated to mimic the functional loss of RTKs (Casci et al., 1999) , with Spry proteins established as negative regulators of FGF-and EGF-induced ERK/MAPK activation (Casci et al., 1999; Hacohen et al., 1998; Kramer et al., 1999) , interfering at the level of FRS2, Shp2, Grb2, C-Raf and B-Raf (Cabrita and Christofori, 2008; Guy et al., 2009 Guy et al., , 2003 Kim and Bar-Sagi, 2004; Mason et al., 2006) . Contrary to this, Spry may even potentiate EGF-induced ERK/ MAPK activation (via reduced EGFR ubiquitination) in certain cellular contexts, whereas it consistently negatively regulates FGFinduced ERK/MAPK signaling (Impagnatiello et al., 2001; Sasaki et al., 2001) . Our results of negative regulation of FGF-induced ERK/MAPK signaling by Spry1 or Spry2 were consistent with other studies ( Representative micrographs of montages of BrdU-labeled lens cells in P9, WT mice lens (A), and Spry1 GOF (B) and Spry2 GOF (C) transgenic mice lenses tracked after 7 days post injection. BrdU was injected at P2, and the tissue was collected after 7 days. Seven days following BrdU injection, an average of 23, 21 and 11 BrdU-labeled epithelial cells migrated into the lens fiber cortex in the WT, Spry1 GOF and Spry2 GOF lens, respectively (A-D). Scale bar, 100 mm. (ii) Quantitative analysis of these BrdUlabeled cells that migrated into lens cortex showed that rate of new secondary fiber differentiation in the Spry2 GOF transgenic lens was significantly lower than that of the WT lens (Student's t-test; n¼ 18; p o0.0005); however, no significant difference was seen in the Spry1 GOF transgenic lens when compared to that of the WT lens (Student's ttest; n ¼18; p 40.1). Error bars represent standard errors. and did not indicate that there is any Spry1-or Spry2-mediated potentiation of EGF-induced ERK/MAPK signaling in lens epithelial cells, which merits further investigation. Interestingly, we noted a heterogeneity in the responsiveness of lens epithelial cells in lens explants to FGF and EGF in vitro, and this may also be the case in situ. Lens epithelial cells are known to be comprised of a heterogenous population, most notably the normally quiescent anterior central epithelial cells compared to the more mitoticallyactive peripheral cells of the germinative zone (Zhou et al., 2006) . This heterogeneity between the different epithelial cells may reside on a number of different factors, including differential high affinity receptor distribution (de Iongh et al., 1997; Collison and Duncan, 2001) , and in the case of our present study, possibly differential levels of Sprouty overexpression in different epithelial cells, with some cells more or less resistant to growth factor-induced ERK1/2-phosphorylation. Further studies in vitro in lens, with more tighter control of Sprouty mis-expression are warranted to better examine the mode of Sprouty activity.
Whilst it has been proposed that hSpry2 has a greater inhibitory potency on the Ras/MAPK signaling pathway than mSpry1 or mSpry4 , possibly accounting for the more severe lens phenotype in our Spry2 GOF lines, this is difficult to compare in our present models given the different modes of Sprouty delivery. Both Spry1 and Spry2 are effective at blocking FGF-induced lens fiber differentiation and concomitant phosphorylation of ERK1/2 phosphorylation in vitro, yet they present distinct but overlapping phenotypes when each is specifically deleted from the postnatal murine lens (see Shin et al. (2012) ).
Spry modifies extracellular matrix
The lens capsule is the continuous basement membrane that is secreted by lens cells (Tholozan and Quinlan, 2007) . The anterior and posterior surfaces of the lens capsule differ in thickness, composition and architecture (Johnson and Beebe, 1984; Cammarata and Spiro, 1985; Cammarata et al., 1986 ). The heterogeneity observed between various regions of the lens capsule may be due to the differential production, deposition or modification of the ECM by the lens cells themselves. Additionally, this may be due to ECM degrading enzymes, namely, the matrix metalloproteinases (MMPs), soluble in the aqueous and vitreous humors (Brown et al., 1994; Huang et al., 1996; De La Paz et al., 1998) . We observed posterior lens capsule thinning in both the Spry1 GOF and Spry2 GOF transgenic lines, ultimately resulting in posterior lens capsule rupture and extrusion of lens fibers into the vitreous chamber. The modification of the anterior lens capsule of the Spry1 GOF or Spry2 GOF transgenic lines, compared to the WT, was dissimilar to each other. For the Spry1 GOF transgenic lens, the anterior capsule appeared to thicken at the time of posterior capsule rupture, and this persisted through to older ages. For the Spry2 GOF transgenic lens, the anterior lens capsule remained thinner than that observed in the WT lens of equivalent age. Due to this inconsistency in the anterior lens capsule of the two transgenic lines, given that this may have been a secondary effect of the thinning and subsequent ruptured posterior lens capsule, we focused primarily on the posterior capsule phenotype.
We examined PI3K/Akt signaling as a potential pathway modified by Spry to regulate ECM synthesis. The Akt signaling pathway has been shown to positively regulate basement membrane formation, in particular certain laminin and type IV collagen isotypes, upon RTK activation (Li et al., 2001a, b) . Furthermore, FGF2 can upregulate α1(I) collagen transcription through PI3K signaling (Ko and Kay, 2005) . We noted in lens explants stimulated with FGF that if we block PI3K/Akt signaling (using the LY294002 inhibitor), there is reduced de novo lens capsular ECM material synthesis compared to explants treated without LY294002. Prior to posterior Fig. 13 . Endogenous levels of phosphorylated ERK1/2 relative to total ERK1/2 in lysates of WT lens, and Spry1 GOF and Spry2 GOF transgenic mice lenses at P21. (A) Representative western blot of the lysates of WT lens, and Spry1 GOF and Spry2 GOF transgenic mice lenses for levels of phosphorylated ERK1/2 (pERK1/2; upper panel), total ERK1/2 (tERK1/2; middle panel) and GAPDH (loading control; lower panel). The pERK1/2 levels in the Spry1 GOF and Spry2 GOF transgenic lenses appeared lower than that of the WT, with total ERK1/2 levels in the Spry1 GOF and Spry2 GOF transgenic lenses appearing slightly higher than that of the WT. GAPDH levels were constant for the 3 genotypes. (B) Quantitative analysis of pERK1/2 levels (relative to total ERK1/2), set to a value of 1 for WT, showed pERK1/2 levels in Spry1 GOF and Spry2 GOF lenses to be 0.35 and 0.71, respectively, both significantly lower than that of the WT lens (Student's t-test; p o0.0005). Error bars represent standard errors. (C) Quantitative analysis of total ERK1/2 levels (relative to GAPDH levels), set to a value of 1 for WT, showed that both Spry1 GOF and Spry2 GOF transgenic lenses had higher basal levels of total ERK1/2, compared to that of WT lens, measuring 1.47 and 1.15, respectively. These ratios were significantly higher than that of WT lens (Student's t-test; Spry1 GOF po 0.0005; Spry2 GOF p o0.005). Error bars represent standard errors. lens capsule rupture, we recorded a decrease in phosphorylation of Akt, albeit not significant, in the Spry1 GOF or Spry2 GOF transgenic lenses. Taken together, it is feasible that Spry-mediated negative regulation of PI3K/Akt signaling may lead to a reduction of ECM that normally contributes to posterior lens capsule thickening. However, we can not rule out that the capsule thinning was due to an increase in ECM degradation, or a combination of both.
MMPs have the ability to degrade and remodel ECM components (Massova et al., 1998; Huang et al., 1996) . MMP-2 and MMP-9 belong to the gelatinase subfamily of MMPs and are known to preferentially digest native collagens (types IV, V and VII), denatured collagens (types I, II and III), and certain proteoglycans and glycoproteins (Brown et al., 1994) . Using lens culture, gelatin zymography and immunofluorescence, we were not able to detect any significant differences in MMP-2 or MMP-9 between the WT lens and the transgenic lens epithelial cells overexpressing Spry1 or Spry2 (data not shown). Aqueous and vitreous humors also contain MMPs (Brown et al., 1994; De La Paz et al., 1998; Huang et al., 1996) , with MMP-9 increasing dramatically in the humor (Huang et al., 1996; Brown et al., 1994; Kosano et al., 1999) of patients with proliferative diabetic retinopathy, or following cataract surgery. As noted earlier, given that Rac1 GTPase activity has been shown to play an essential role in lens ECM turnover (Maddala et al., 2011) and Spry2 can limit Rac1 activation (Poppleton et al., 2004) , this may be the contributing mechanism to the lens capsule rupture. It would be interesting to identify other Spry targets that influence ECM breakdown or remodeling.
In summary, we have shown Spry to play an important inhibitory role in the regulation of lens cell proliferation and differentiation, potentially interfering with the FGF-and EGF-mediated MAPK/ERK1/2 signaling pathway. This primarily resulted in aberrant lens development and impaired growth of the eye, Representative micrographs of phosphorylated ERK1/2 in epithelial explants of WT mice lens, and Spry1 GOF and Spry2 GOF transgenic mice lenses at P7, following a treatment to increasing doses of FGF2. Explants were labeled for pERK1/2 (green), and nuclei counterstained with propidium iodide (red). WT lens (A, D, G, and J) and Spry1 GOF (B, E, H, and K) and Spry2 GOF (C, F, I, and L) transgenic lenses were explanted. The explants were treated for 20 min with 5 ng/ml FGF2 (D, E, and F), 50 ng/ml FGF2 (G, H, and I), 100 ng/ml FGF2 (J, K, and L), or with no FGF (control; A, B, and C). With no growth factor treatment, the basal levels of pERK1/2 expression in the central epithelial cells of WT lens, and Spry1 GOF and Spry2 GOF transgenic lenses were very low and similar to each other (A-C). Treatment with 5 ng/ml FGF2 resulted in slight increase in pERK1/2 level in some isolated central epithelial cells of the WT, Spry1 GOF and Spry2 GOF lens explants (D-F, arrows). With 50 ng/ml FGF2 treatment, the central lens epithelial cells of the WT mice showed homogenously higher pERK1/2 labeling (G), while the Spry1 GOF and Spry2 GOF transgenic lens explant cells had markedly lower pERK1/2 levels (H, I) to that seen in WT lens (G). With 100 ng/ml FGF2; however, the Spry1 GOF and Spry2 GOF transgenic lens explant cells, displayed similar widespread pERK1/2 levels to that of the WT lens explant cells, with some isolated cells in the Spry1 GOF and Spry2 GOF transgenic lens explants failing to label strongly for pERK1/2 (K, L, arrowheads). Scale bar, 10 mm. consistent with many of the features previously reported in lens of mice deficient for ERK2 (Upadhya et al., 2013) . This study highlights the importance of tightly regulating intracellular signaling to orchestrate tissue morphogenesis and growth, with ERK1/2 signaling established as a key mediator of lens cellular processes. This regulation of FGF-induced ERK1/2 phosphorylation by Spry is important for lens cells, as the strength and duration of growth factor-induced ERK1/2 activation is reported to determine lens cell fate (Iyengar et al., 2007; Wang et al., 2010) . Spry can negatively regulate lens cell proliferation and fiber cell differentiation in vivo and in vitro, with Spry playing an important role in the maintenance of lens growth and the determination of lens and eye size.
